CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the 150^th Annual American Neurological Association (ANA) conference held September 13-16, 2025 in Baltimore, Maryland.

Read more at globenewswire.com